Let's focus on what we can do!

By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Ataxia
  • >
  • Agilis Biotherapeutics and Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement for Friedreich’s … – Business Wire (press release)

Agilis Biotherapeutics and Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement for Friedreich’s … – Business Wire (press release)

Friday, 19 February, 2016

Agilis Biotherapeutics and Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement for Friedreich’s … – Business Wire (press release)

It is the most common inherited ataxia, with 1 in every 100 people being carriers of a mutated FXN gene. FA typically arises between the ages of 5 and 15 and manifests as difficulty with balance and coordination. Over time, the disease progresses to an ...

Read More

Source:Agilis Biotherapeutics and Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement for Friedreich's ... - Business Wire (press release)

Categories :
  • Ataxia
  • Latest Headlines
  • Uncategorized
Socials :

Recent posts